HRP20040994A2 - Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention - Google Patents
Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention Download PDFInfo
- Publication number
- HRP20040994A2 HRP20040994A2 HR20040994A HRP20040994A HRP20040994A2 HR P20040994 A2 HRP20040994 A2 HR P20040994A2 HR 20040994 A HR20040994 A HR 20040994A HR P20040994 A HRP20040994 A HR P20040994A HR P20040994 A2 HRP20040994 A2 HR P20040994A2
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical combination
- long
- treatment
- prostatic hyperplasia
- benign prostatic
- Prior art date
Links
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 11
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract description 11
- 206010046555 Urinary retention Diseases 0.000 title claims abstract description 10
- 230000001154 acute effect Effects 0.000 title claims abstract description 8
- 230000007774 longterm Effects 0.000 title claims abstract description 7
- 230000002265 prevention Effects 0.000 title claims abstract description 5
- 238000011282 treatment Methods 0.000 title claims description 8
- ZZIZZTHXZRDOFM-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethyl-[1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl]azanium;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-UHFFFAOYSA-N 0.000 claims description 19
- 229960003198 tamsulosin hydrochloride Drugs 0.000 claims description 19
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims description 12
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims description 10
- 229960004039 finasteride Drugs 0.000 claims description 10
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims description 10
- 229960004199 dutasteride Drugs 0.000 claims description 9
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical group O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 claims description 9
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 claims description 6
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 229960002613 tamsulosin Drugs 0.000 claims description 6
- 102000001708 Protein Isoforms Human genes 0.000 claims description 5
- 108010029485 Protein Isoforms Proteins 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 238000011866 long-term treatment Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- 210000002307 prostate Anatomy 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 10
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003054 hormonal effect Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010051482 Prostatomegaly Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 229960003473 androstanolone Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 description 1
- 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010046542 Urinary hesitation Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000008003 autocrine effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 108091007930 cytoplasmic receptors Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- -1 elixirs Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940099831 tamsulosin and dutasteride Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2002118392 DE10218392A1 (de) | 2002-04-24 | 2002-04-24 | Verwendung von Arzneimittelkombinationen zur Behandlung von benigner Prostatahyperplasie |
| DE2002118611 DE10218611A1 (de) | 2002-04-25 | 2002-04-25 | Verwendung einer Tamsulosin enthaltenden Arzneimittelkombination zur Behandlung von benigner Prostatahyperplasie |
| PCT/EP2003/004034 WO2003090753A1 (en) | 2002-04-24 | 2003-04-17 | Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20040994A2 true HRP20040994A2 (en) | 2005-02-28 |
Family
ID=29271571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20040994A HRP20040994A2 (en) | 2002-04-24 | 2004-10-22 | Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20030225118A1 (de) |
| EP (2) | EP1501517B1 (de) |
| JP (1) | JP2005524693A (de) |
| CN (1) | CN1646135A (de) |
| AT (1) | ATE361075T1 (de) |
| AU (1) | AU2003227643A1 (de) |
| BR (1) | BR0309435A (de) |
| CA (1) | CA2479992A1 (de) |
| CY (1) | CY1107674T1 (de) |
| DE (1) | DE60313603T2 (de) |
| DK (1) | DK1501517T3 (de) |
| EA (1) | EA008377B1 (de) |
| ES (1) | ES2287474T3 (de) |
| HR (1) | HRP20040994A2 (de) |
| IL (1) | IL163976A0 (de) |
| MX (1) | MXPA04010408A (de) |
| NO (1) | NO20044333L (de) |
| NZ (1) | NZ536514A (de) |
| PL (1) | PL371430A1 (de) |
| PT (1) | PT1501517E (de) |
| RS (1) | RS92304A (de) |
| WO (1) | WO2003090753A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0309435A (pt) * | 2002-04-24 | 2005-02-15 | Boehringer Ingelheim Pharma | Combinação farmacêutica para o tratamento de hiperplasia prostática benigna ou para a prevenção a longo prazo de retenção urinária aguda |
| KR20060124603A (ko) * | 2003-11-03 | 2006-12-05 | 베링거 인겔하임 인터내셔날 게엠베하 | 베타-3-아드레날린 수용체 효능제 및 알파 길항제 및/또는5-알파-리덕타제 억제제를 함유하는 약제학적 조성물 |
| US7601994B2 (en) * | 2003-11-14 | 2009-10-13 | Semiconductor Energy Laboratory Co., Ltd. | Display device and method for manufacturing the same |
| WO2006055659A2 (en) * | 2004-11-15 | 2006-05-26 | Smithkline Beecham Corporation | Fixed dose combination op dutasteride and tamsulosin |
| CN102309495A (zh) * | 2010-06-30 | 2012-01-11 | 北京润德康医药技术有限公司 | 一种复方制剂及其制备方法 |
| WO2012110092A1 (en) | 2011-02-17 | 2012-08-23 | Synthon Bv | Tamsulosin derivatives |
| BRPI1103204A2 (pt) * | 2011-06-03 | 2014-02-25 | Eurofarma Lab S A | Composição farmacêutica para o tratamento de hiperplasia prostática benigna |
| WO2013123965A1 (en) | 2012-02-20 | 2013-08-29 | Synthon Bv | A fixed dose pharmaceutical formulation |
| US10596127B2 (en) | 2013-03-14 | 2020-03-24 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| BR102013020508B1 (pt) * | 2013-08-12 | 2021-01-12 | Ems S/A. | Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem |
| ES2555485T1 (es) | 2014-05-26 | 2016-01-04 | Galenicum Health S.L. | Composiciones farmacéuticas que contienen un agente activo |
| AU2016331879A1 (en) * | 2015-09-30 | 2018-05-17 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| US10172910B2 (en) * | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
| CN115969860A (zh) * | 2021-10-14 | 2023-04-18 | 上海汇伦医药股份有限公司 | 一种药物组合物及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391825A (en) * | 1980-02-08 | 1995-02-21 | Yamanouchi Pharmaceutical Co., Ltd. | Sulfamoyl substituted phenethylamine intermediates |
| JPS56110665A (en) | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Sulfamoyl-substituted phenetylamine derivative and its preparation |
| US4760071A (en) | 1984-02-27 | 1988-07-26 | Merck & Co., Inc. | 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors |
| IL74365A (en) | 1984-02-27 | 1990-07-26 | Merck & Co Inc | 17beta-(n-t.-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one and pharmaceutical compositions containing it |
| US4772475A (en) | 1985-03-08 | 1988-09-20 | Yamanouchi Pharmaceutical Co., Ltd. | Controlled-release multiple units pharmaceutical formulation |
| EP0285383B1 (de) | 1987-04-03 | 1994-03-16 | Merck & Co. Inc. | Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen |
| EP0285382B1 (de) | 1987-04-03 | 1994-04-13 | Merck & Co. Inc. | Behandlung von androgener Alopecia mit 17-bêta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen |
| IL101243A (en) * | 1991-03-20 | 1999-12-22 | Merck & Co Inc | Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history |
| TW369521B (en) | 1993-09-17 | 1999-09-11 | Smithkline Beecham Corp | Androstenone derivative |
| TW382595B (en) | 1993-10-15 | 2000-02-21 | Merck & Co Inc | Pharmaceutical composition for use in arresting and reversing androgenic alopecia |
| US6423719B1 (en) * | 1999-02-16 | 2002-07-23 | Upsher-Smith Laboratories, Inc. | Method for treating benign prostate hyperplasia |
| WO2001021167A1 (en) * | 1999-09-22 | 2001-03-29 | Merck & Co., Inc. | Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein |
| BR0309435A (pt) * | 2002-04-24 | 2005-02-15 | Boehringer Ingelheim Pharma | Combinação farmacêutica para o tratamento de hiperplasia prostática benigna ou para a prevenção a longo prazo de retenção urinária aguda |
-
2003
- 2003-04-17 BR BR0309435-9A patent/BR0309435A/pt not_active Expired - Fee Related
- 2003-04-17 PL PL03371430A patent/PL371430A1/xx not_active Application Discontinuation
- 2003-04-17 JP JP2003587387A patent/JP2005524693A/ja active Pending
- 2003-04-17 ES ES03725053T patent/ES2287474T3/es not_active Expired - Lifetime
- 2003-04-17 CA CA002479992A patent/CA2479992A1/en not_active Abandoned
- 2003-04-17 AU AU2003227643A patent/AU2003227643A1/en not_active Abandoned
- 2003-04-17 EA EA200401340A patent/EA008377B1/ru not_active IP Right Cessation
- 2003-04-17 IL IL16397603A patent/IL163976A0/xx unknown
- 2003-04-17 AT AT03725053T patent/ATE361075T1/de active
- 2003-04-17 NZ NZ536514A patent/NZ536514A/en unknown
- 2003-04-17 CN CNA038089300A patent/CN1646135A/zh active Pending
- 2003-04-17 EP EP03725053A patent/EP1501517B1/de not_active Revoked
- 2003-04-17 RS YU92304A patent/RS92304A/sr unknown
- 2003-04-17 PT PT03725053T patent/PT1501517E/pt unknown
- 2003-04-17 DE DE60313603T patent/DE60313603T2/de not_active Revoked
- 2003-04-17 DK DK03725053T patent/DK1501517T3/da active
- 2003-04-17 WO PCT/EP2003/004034 patent/WO2003090753A1/en active IP Right Grant
- 2003-04-17 MX MXPA04010408A patent/MXPA04010408A/es active IP Right Grant
- 2003-04-17 EP EP06122312A patent/EP1743656A3/de not_active Withdrawn
- 2003-04-24 US US10/422,509 patent/US20030225118A1/en not_active Abandoned
-
2004
- 2004-10-12 NO NO20044333A patent/NO20044333L/no not_active Application Discontinuation
- 2004-10-22 HR HR20040994A patent/HRP20040994A2/hr not_active Application Discontinuation
-
2007
- 2007-04-06 US US11/697,470 patent/US20070197666A1/en not_active Abandoned
- 2007-06-14 CY CY20071100794T patent/CY1107674T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1743656A3 (de) | 2007-03-07 |
| BR0309435A (pt) | 2005-02-15 |
| ATE361075T1 (de) | 2007-05-15 |
| WO2003090753A8 (en) | 2004-11-04 |
| WO2003090753A1 (en) | 2003-11-06 |
| PL371430A1 (en) | 2005-06-13 |
| EP1501517A1 (de) | 2005-02-02 |
| EA200401340A1 (ru) | 2005-06-30 |
| DE60313603D1 (de) | 2007-06-14 |
| US20030225118A1 (en) | 2003-12-04 |
| EA008377B1 (ru) | 2007-04-27 |
| PT1501517E (pt) | 2007-05-31 |
| US20070197666A1 (en) | 2007-08-23 |
| MXPA04010408A (es) | 2005-02-17 |
| DE60313603T2 (de) | 2008-01-03 |
| JP2005524693A (ja) | 2005-08-18 |
| DK1501517T3 (da) | 2007-06-11 |
| CN1646135A (zh) | 2005-07-27 |
| NZ536514A (en) | 2006-11-30 |
| EP1501517B1 (de) | 2007-05-02 |
| CY1107674T1 (el) | 2013-04-18 |
| AU2003227643A1 (en) | 2003-11-10 |
| RS92304A (en) | 2006-10-27 |
| IL163976A0 (en) | 2005-12-18 |
| EP1743656A2 (de) | 2007-01-17 |
| ES2287474T3 (es) | 2007-12-16 |
| NO20044333L (no) | 2004-11-09 |
| CA2479992A1 (en) | 2003-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070197666A1 (en) | Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention | |
| AU2017336363B2 (en) | Methods of treating uterine fibroids and endometriosis | |
| US20050272795A1 (en) | Prevention and treatment of benign prostatic hyperplasia | |
| IL145838A (en) | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis | |
| US20020147155A1 (en) | Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands | |
| AU743196B2 (en) | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents | |
| Bernoulli et al. | Urodynamic changes in a noble rat model for nonbacterial prostatic inflammation | |
| EP1613327B1 (de) | Zusammensetzung die tamsulosin und ein nichtsteroides entzündungshemmendes mittel enthält | |
| Sarkar | The potential of mifepristone (RU486) as a female contraceptive drug | |
| ZA200407057B (en) | Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention | |
| WO2006015283A2 (en) | Treatment of benign prostatic hyperplasia | |
| KR20050018661A (ko) | 양성 전립선 비대증의 치료 또는 급성 요폐의 장기간예방을 위한 약제학적 배합물 | |
| Barra et al. | Vilaprisan. Progesterone receptor modulator, Treatment of uterine fibroids | |
| Silverstein et al. | Management of Benign Prostatic Hyperplasia: Alternatives to Standard Therapy | |
| DE10218611A1 (de) | Verwendung einer Tamsulosin enthaltenden Arzneimittelkombination zur Behandlung von benigner Prostatahyperplasie | |
| CZ20002138A3 (cs) | Použití inhibitorů aromatasy při léčbě sníženého poměru hladin androgenu k estrogenu a dyssynergie svalu vypuzovače a svěraěe močové trubice u člověka a způsob studia této dyssynergie u samečků hlodavců |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20080417 Year of fee payment: 6 |
|
| OBST | Application withdrawn |